Effects of Different Biological Therapies on S1/S2 Antibody Response to SARS-CoV-2 Vaccination in a Cohort of Patients with Inflammatory Bowel Disease
Authors:
- Nunzia LabarileNLNunzia Labarile
- Fabio CastellanaFabio Castellana
- Annamaria SilaASAnnamaria Sila
- Pasqua Letizia PesolePPPasqua Letizia Pesole
- Sergio ColettaSCSergio Coletta
- Margherita CurloMCMargherita Curlo
- Rodolfo SardoneRSRodolfo Sardone
- Gianluigi GiannelliGianluigi Giannelli
- Mauro MastronardiMauro Mastronardi
Open Access
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has affected the entire planet. The objectives of our study were to compare responses to the vaccine (Pfizer-Biontech COMIRNATY) in a population of patients with intestinal bowel syndrome undergoing different biological therapies or conventional therapy. The study recruited 390 patients who received the first vaccination dose during the dedicated vaccination campaign for inflammatory bowel disease (IBD) patients. The inclusion criteria were a diagnosis of CD or UC and complete vaccination with the Pfizer–BioNTech COVID-19 (Comirnaty) vaccine. The exclusion criteria were other significant diseases or important therapies under way or contraindications to vaccination according to the European drug surveillance recommendations. Linear rank models were run to assess the association between the different therapies and S1/S2 antibodies at three different times. The models showed that in patients with IBD receiving Vedolizumab a significant increase in mean IgG levels was observed, independently of other therapies and confounding factors (β: 57.45, 95% CI 19.62 to 19.00). This study confirmed the complete antibody response to vaccination against COVID-19 in patients with IBD undergoing biological therapy—particularly Vedolizumab treatment—but also a reduced immune response due to concomitant steroid therapy.Keywords
Funding Information
- Italian Ministry of Health—Ricerca Corrente 2021
This publication has 28 references indexed in Scilit:
- Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel DiseasesClinical Gastroenterology and Hepatology, 2019
- Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel DiseasesGastroenterology, 2018
- Antibody Response to Hepatitis B Virus Vaccine is Impaired in Patients With Inflammatory Bowel Disease on Infliximab TherapyInflammatory Bowel Diseases, 2018
- Efficacy of Hepatitis A Vaccination and Factors Impacting on Seroconversion in Patients with Inflammatory Bowel DiseaseInflammatory Bowel Diseases, 2014
- Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: A prospective study*Inflammatory Bowel Diseases, 2012
- Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel diseaseGut, 2011
- Management of Crohn's Disease in AdultsAmerican Journal of Gastroenterology, 2009
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005
- A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injuryNature Medicine, 2005
- Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.1976